Employees: 735
Size Jiangsu Aidea Pharmaceutical (688488.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $672M, the 2984th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥10.59 on 18 Nov 2026.
Performance Over six months the shares fell 35.0%, against -6.0% for the median peer and -20.0% for the China market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue grew 7.1% over the last twelve months (peer median +11.6%); the operating margin is 7.9% (peer median 10.7%).
Valuation It trades at 112.1× forward earnings against a peer median of 17.0× (most expensive of 9).
Price implies For today's price to make sense, revenue must grow about 32% a year for seven years (Req g). Recent delivered growth is +20%, so the hurdle is +12 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.7 points below its cost of capital (8.8% WACC).
Next results Next results expected around 9 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥717M | CN¥711M | CN¥412M | CN¥409M | CN¥244M |
| Revenue growth | — | +73% | +1% | +68% | — |
| Gross profit | CN¥514M | CN¥453M | CN¥198M | CN¥158M | CN¥78.4M |
| EBITDA | n/a | CN¥89.6M | -CN¥94.9M | -CN¥58.3M | -CN¥130M |
| Net income | CN¥7.12M | -CN¥19.5M | -CN¥141M | -CN¥76.1M | -CN¥124M |
| Free cash flow | CN¥1.50M | -CN¥28.8M | -CN¥77.9M | -CN¥230M | -CN¥224M |
| Capital expenditure | CN¥67.6M | CN¥47.9M | CN¥44.6M | CN¥71.2M | CN¥140M |
| Total debt | CN¥698M | CN¥576M | CN¥521M | CN¥418M | CN¥221M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688488.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -25.2% | -2.8% | lowest of 21 |
| 6-month return | -35.0% | -6.0% | 2nd lowest of 21 |
| Distance from 52-week high | -53.0% | -28.2% | 3rd lowest of 21 |
| Revenue growth (TTM) | +7.1% | +11.6% | 8th lowest of 18 |
| Operating margin | 7.9% | 10.7% | 7th lowest of 18 |
| Forward P/E | 112.1× | 17.0× | most expensive of 9 |
| Growth the price implies (Req g, 7 yrs) | 31.9% | 6.5% | 2nd most demanding of 9 |
| Growth delivered (Del g) | +19.8% | +7.1% | 2nd highest of 9 |
| Hurdle (Req g minus delivered) | +12.0 pp | -0.6 pp | 3rd most demanding of 9 |
| ROIC minus cost of capital | -2.7 pp | -0.0 pp | 7th lowest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jiangsu Aidea Pharmaceutical 688488.SS | China | $672M | -35% | +7% | 8% | 112.1× | 31.9% | +19.8% |
| Philogen PHIL.MI | Italy | $672M | -11% | +295% | 79% | 10.1× | n/a | n/a |
| Annexon ANNX | United States | $671M | -30% | n/a | n/a | n/a | n/a | n/a |
| Youcare Pharmaceutical 688658.SS | China | $674M | -49% | -7% | -13% | 24.9× | n/a | n/a |
| Yabao Pharmaceutical 600351.SS | China | $678M | 0% | -3% | 16% | n/a | -8.3% | -2.8% |
| Sun Pharma Advanced Research SPARC.NS | India | $660M | +6% | +3,141% | 84% | n/a | n/a | n/a |
| Shandong Wit Dyne Health 000915.SZ | China | $687M | -31% | -36% | 36% | 9.1× | n/a | n/a |
| Earth 4985.T | Japan | $687M | +7% | +4% | 4% | 18.0× | -1.6% | -1.8% |
| FDC FDC.NS | India | $653M | +3% | +10% | 14% | n/a | 25.2% | +10.3% |
| Nuvectis Pharma NVCT | United States | $698M | +91% | n/a | n/a | n/a | n/a | n/a |
| Innova Captab INNOVACAP.NS | India | $645M | +20% | +37% | 12% | 32.2× | 27.1% | +31.4% |
| HPGC Renmintongtai Pharmaceutical 600829.SS | China | $701M | -6% | +4% | 2% | n/a | 4.0% | +5.3% |
| Hainan Haiyao 000566.SZ | China | $642M | -18% | -18% | -50% | n/a | n/a | n/a |
| Beijing Beilu Pharmaceutical 300016.SZ | China | $641M | -19% | +23% | 11% | 79.7× | 9.1% | +7.9% |
| Center Laboratories 4123.TWO | Taiwan | $639M | -29% | +14% | 9% | n/a | 36.3% | +16.2% |
| Mochida Pharmaceutical 4534.T | Japan | $714M | -3% | +16% | 10% | 16.1× | n/a | n/a |
| Zhejiang Wecome Pharmaceutical 300878.SZ | China | $632M | -18% | +92% | -41% | n/a | n/a | n/a |
| China Traditional Chinese Medicine 0570.HK | Hong Kong | $716M | -31% | -16% | 0% | n/a | n/a | n/a |
| Arbutus Biopharma ABUS | United States | $630M | -6% | +1,143% | 80% | n/a | n/a | n/a |
| Hunan Fangsheng Pharmaceutical 603998.SS | China | $719M | -1% | +12% | 20% | 13.7× | -4.8% | +6.4% |
| Sagimet Biosciences SGMT | United States | $722M | +52% | n/a | n/a | n/a | n/a | n/a |